No Data
No Data
Fosun Pharma Reveals Henlius Buyout Terms
Fosun Pharma (02196) provides guarantees for its subsidiaries.
Fosun Pharma (02196) announced that the company intends to apply to Guangfa Bank for the principal for its holding subsidiary Chaohui Pharmaceutical...
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Fosun Pharma Schedules EGM for Key Decisions
Fosun Pharma (02196) intends to provide a guarantee for the 30 million yuan credit line applied by its subsidiary Hanlin Pharma.
Fosun Pharma (02196) issued an announcement that on August 16, 2024, its subsidiary, Shanghai Henlius, will ...
Revance has been acquired for 0.924 billion U.S. dollars! Fosun Pharma (600196.SH) holds exclusive commercialization rights for its star botulinum toxin product in China.
Revance is acquired for $0.924 billion.
No Data